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BACKGROUND
Combined immunodeficiencies are marked by inborn errors of T-cell immunity in 
which the T cells that are present are quantitatively or functionally deficient. Im-
paired humoral immunity is also common. Patients have severe infections, auto-
immunity, or both. The specific molecular, cellular, and clinical features of many 
types of combined immunodeficiencies remain unknown.
METHODS
We performed genetic and cellular immunologic studies involving five unrelated 
children with early-onset invasive bacterial and viral infections, lymphopenia, and 
defective T-cell, B-cell, and natural killer (NK)–cell responses. Two patients died 
early in childhood; after allogeneic hematopoietic stem-cell transplantation, the 
other three had normalization of T-cell function and clinical improvement.
RESULTS
We identified biallelic mutations in the dedicator of cytokinesis 2 gene (DOCK2) in 
these five patients. RAC1 activation was impaired in the T cells. Chemokine-induced 
migration and actin polymerization were defective in the T cells, B cells, and NK 
cells. NK-cell degranulation was also affected. Interferon-α and interferon-λ pro-
duction by peripheral-blood mononuclear cells was diminished after viral infec-
tion. Moreover, in DOCK2-deficient fibroblasts, viral replication was increased and 
virus-induced cell death was enhanced; these conditions were normalized by treat-
ment with interferon alfa-2b or after expression of wild-type DOCK2.
CONCLUSIONS
Autosomal recessive DOCK2 deficiency is a new mendelian disorder with pleiotropic 
defects of hematopoietic and nonhematopoietic immunity. Children with clinical 
features of combined immunodeficiencies, especially with early-onset, invasive 
infections, may have this condition. (Supported by the National Institutes of Health 
and others.)
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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Combined immunodeficiencies com-prise a heterogeneous group of inherited defects of the immune system that are 
characterized by quantitative or qualitative defects 
of T lymphocytes. These defects are associated 
with primary or secondary defects of B lympho-
cytes.1 In patients with combined immunodeficien-
cies, impairment of adaptive immunity causes 
increased susceptibility to early-onset, severe in-
fections with a variety of viruses, bacteria, fungi, 
and parasites.1,2 Autoimmune manifestations, 
allergies, and cancers can also occur.2
Identification of gene defects that cause com-
bined immunodeficiencies has helped patients 
considerably, provided new and important in-
sights into mechanisms governing T-cell devel-
opment and function in humans,2 and led to an 
understanding of the molecular and cellular 
basis of common conditions, including autoim-
munity, allergy, inflammation, and cancer. How-
ever, the specific molecular, cellular, and clinical 
features of many combined immunodeficiencies 
remain poorly defined.
Next-generation sequencing has revolution-
ized studies of human genetic diseases, enabling 
the identification of new causative genetic varia-
tions in an increasing number of patients with 
primary immunodeficiencies.3-7 Here we report 
on human dedicator of cytokinesis 2 (DOCK2) 
deficiency as a combined immunodeficiency in 
five unrelated patients of various ethnic origins. 
These patients presented with a distinctive clini-
cal phenotype of early-onset, invasive infections 
that were associated with a broad spectrum of 
defects in hematopoietic and nonhematopoietic 
immunity.
Me thods
Study Oversight
The study was approved by the institutional re-
view boards of the Kuwait Ministry of Health, 
INSERM, Rockefeller University, the Medical 
University of Vienna, Ankara University Medical 
School, Boston Children’s Hospital, and Duke 
University School of Medicine. Written informed 
consent was obtained from the patients’ parents 
or guardians.
Case Patients
Pedigrees of the five unrelated index patients are 
shown in Figure 1A, and Figure S1 in the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org. Clinical and labora-
tory data are summarized in Table 1.
Patient 1, a boy born to consanguineous 
Lebanese parents, presented at 3 months of age 
with respiratory syncytial virus bronchiolitis, 
followed by recurrent episodes of pneumonia. At 
5 months of age, severe T-cell lymphopenia and 
markedly reduced in vitro T-cell proliferation 
were observed (Table 1). At 9 months of age, 
after myeloablative conditioning with busulfan 
and fludarabine, he underwent T-cell–depleted 
haploidentical hematopoietic stem-cell transplan-
tation (HSCT) from his father. He was well and 
was not receiving intravenous immune globulin 
replacement therapy 13 months after undergo-
ing HSCT.
In the first 2 years of life, Patient 2, a girl born 
to nonconsanguineous Finnish parents, had re-
current otitis media, pneumonia, diarrhea, and 
three episodes of thrombocytopenia that resolved 
spontaneously. At 2.5 years of age, vaccine strain–
related varicella developed, with liver and lung 
involvement and multiple pulmonary infiltrates, 
and the patient required ventilatory support 
(Fig. 1B). Several months later, computed tomog-
Figure 1 (facing page). Identification of DOCK2 Muta-
tions in Patients with Combined Immunodeficiency.
Panel A shows the pedigrees of the five families of the 
patients with DOCK2 mutations in the study (Patients 
1 through 5, solid symbols). Circles represent female 
family members, and squares male family members.  
A slash through a symbol represents a deceased per-
son. Chromatograms corresponding to the identified 
DOCK2 mutations in these patients and heterozygous 
carriers for each family are shown. Panel B shows the 
clinical spectrum of DOCK2 deficiency (from left to 
right): pneumonia requiring intubation in Patient 2, 
rash with vesicular lesions due to varicella in Patient 3, 
and neutrophil infiltrate in colonic lamina propria and 
crypt epithelium consistent with focal active colitis in 
Patient 4 (hematoxylin and eosin, low magnification). 
Panel C shows the distribution of the identified muta-
tions relative to the DOCK2 protein structure depicting 
the SRC homology 3 (SH3) domain, the DOCK homol-
ogy region 1 (DHR-1) domain, and the DOCK homolo-
gy region 2 (DHR-2) domain. Panel D shows the im-
munoblot analysis of protein lysates from Epstein–Barr 
virus (EBV)–transformed B-cell lines from Patient 3 
and two healthy controls and protein lysates from T-cell 
lines from Patients 1 and 2 and a control. Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) served as 
protein-loading control.
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raphy of the chest showed a new pulmonary in-
filtrate (Fig. S2A in the Supplementary Appendix). 
A lung biopsy revealed granulomatous inflamma-
tion (Fig. S2B in the Supplementary Appendix) 
with acid-fast bacilli. Mycobacterium avium was 
cultured from the biopsy specimen, and human 
herpesvirus-6 DNA was detected. Immunologic 
investigations revealed T-cell and B-cell lympho-
penia, defective in vitro T-cell proliferation, and 
a lack of specific antibody responses (Table 1), 
all of which were consistent with combined im-
munodeficiency. At the age of 3.8 years, after 
reduced-intensity conditioning with the use of 
treosulfan, fludarabine, and alemtuzumab, she 
underwent HLA-matched unrelated-donor HSCT. 
She was well 8 months after HSCT.
Patient 3, a boy born to consanguineous 
Turkish parents, had recurrent respiratory tract 
infections from the age of 3 months. At 6 years 
of age, he had two episodes of meningoenceph-
alitis. On the basis of examination of the cere-
brospinal fluid (1000 leukocytes per cubic milli-
meter, 74% of which were lymphocytes), high 
serum amylase levels (762 U per liter), and detec-
tion of mumps-specific IgM, this condition was 
presumed to be due to mumps virus infection 
that was concurrent with an outbreak of mumps 
at the child’s school. At the age of 6.3 years, 
severe varicella (Fig. 1B) with alveolar infiltrates 
developed, and child’s illness rapidly progressed 
to multiorgan failure and death. Laboratory stud-
ies during the patient’s hospitalization showed 
severe T-cell lymphopenia, impaired T-cell acti-
vation, and a lack of antibody responses to vari-
cella–zoster virus (Table 1). A postmortem ex-
amination of the patient’s liver and lungs 
revealed coagulation necrosis, apoptosis, inflam-
matory infiltrates with neutrophils and mono-
cytes, and nuclear inclusion bodies within pneu-
mocytes; the latter findings were consistent with 
viral pneumonitis (Fig. S2C and S2D in the 
Supplementary Appendix).
Patient 4, a boy born to consanguineous 
Turkish parents, had neonatal-onset chronic diar-
rhea with mucus and recurrent episodes of fever 
and oral moniliasis. A liver biopsy, performed at 
3 months of age because of persistently elevated 
aminotransferase levels, revealed macrovesicular 
steatosis, nonnecrotic eosinophilic granuloma-
like lesions, and lobular inflammation (Fig. S2E 
in the Supplementary Appendix). During hospi-
tal admission when the boy was 1 year of age, T
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growth failure (body weight, 4.5 kg [3.5 kg below 
the 3rd percentile] and length, 64 cm [9 cm below 
the 3rd percentile]), a nodular erythematous lesion 
at the site of bacille Calmette–Guérin vaccina-
tion, and hepatomegaly were detected. In addition, 
histopathological analysis of the colon revealed 
focal active colitis (Fig. 1B) that was associated 
with a paucity of B cells, plasma cells, and to a 
lesser extent T cells in the lamina propria of the 
colon. Immunologic investigations (Table 1) re-
vealed T-cell lymphopenia and defective T-cell 
activation in response to phytohemagglutinin. 
Subsequently, multiple episodes of pneumonia 
due to parainfluenza virus type 3 and adenovirus 
developed. The patient had several episodes of 
cytomegalovirus reactivation and died from Kleb-
siella pneumoniae sepsis at 20 months of age.
Patient 5, a Hispanic boy born to nonconsan-
guineous parents from Honduras and Nicaragua, 
presented at the age of 4 months with interstitial 
pneumonia that responded to high-dose trime-
thoprim–sulfamethoxazole. Immunologic find-
ings were consistent with combined immunode-
ficiency (Table 1). At 2 years of age, a rectal 
fistula developed. At 3 years of age, he received 
an HSCT from his HLA-identical brother after 
conditioning with myeloablative doses of busul-
fan and cyclophosphamide. This patient was 
well and was not receiving intravenous immune 
globulin replacement therapy 17.5 years after 
transplantation.
Genetic, Immunologic, and Biochemical 
Analyses
Details of the methods for whole-exome sequenc-
ing, genomewide linkage analysis, homozygosity 
mapping, and sequencing analysis are provided 
in the Supplementary Appendix. In addition, the 
generation of T-cell, B-cell, and natural killer 
(NK)–cell lines are described in detail in the 
Supplementary Appendix, as are immunologic 
and biochemical studies of hematopoietic and 
nonhematopoietic cells.
R esult s
Immunologic Abnormalities
In all five patients, T-cell lymphopenia and im-
paired in vitro T-cell activation in response to 
phytohemagglutinin were detected (Table 1). 
Maternal T-cell engraftment was ruled out in all 
the patients. More detailed immunologic analyses 
that were performed in Patients 1, 2, and 5 re-
vealed a markedly reduced proportion of naive 
(CD45RA+CCR7+) CD4+ and CD8+ T lympho-
cytes that were associated with an increased pro-
portion of effector memory (CD45RA−CCR7−) 
CD4+ T lymphocytes and of either effector 
memory or CD45RA+CCR7− TEMRA CD8+ T lym-
phocytes (Table 1). B-lymphocyte counts were 
reduced in Patients 2 and 4 (Table 1). Despite 
relatively normal serum levels of IgG and IgM, 
Patients 2, 4, and 5 had defective antibody pro-
duction to T-cell–dependent immunization anti-
gens (Table 1). Finally, in Patients 2 and 4, levels 
of T-cell–receptor excision circles, a marker of 
active thymopoiesis, were markedly reduced in 
dried blood spots obtained at birth (Table 1).
Identification of Biallelic Deleterious 
Mutations in DOCK2
Whole-exome sequencing was performed to eluci-
date the genetic basis of the patients’ combined 
immunodeficiencies. Linkage analysis or homo-
zygosity mapping were also performed in Patients 
3 and 4, who were born to consanguineous par-
ents. In Patients 1, 3, and 4, we selected genes 
harboring previously unreported homozygous 
variants, and in Patients 2 and 5 (for whom no 
parental consanguinity was known) we selected 
genes bearing two or more variants (Table S1 in 
the Supplementary Appendix). Biallelic muta-
tions in DOCK2 were identified and confirmed by 
means of Sanger sequencing in all five patients 
(Fig. 1A). No other gene harbored biallelic mu-
tations in two or more patients. Patients 1 and 4 
were homozygous for DOCK2 dinucleotide inser-
tions leading to frameshift and premature termi-
nation, Patient 3 was homozygous for a missense 
mutation, and Patients 2 and 5 were compound 
heterozygotes for different missense and non-
sense DOCK2 mutations (Fig. 1A). Multiple se-
quence alignment showed that all of the three 
missense mutations affect evolutionarily con-
served residues (Fig. S3 in the Supplementary 
Appendix). Intrafamilial segregation was consis-
tent with autosomal recessive inheritance with 
complete penetrance (Fig. S1 in the Supplemen-
tary Appendix). Collectively, we identified seven 
distinct rare mutations in DOCK2 in five patients 
of various ethnic origins; four of these muta-
tions led to premature termination, and three 
were predicted deleterious missense mutations 
affecting conserved residues of DOCK2 (Fig. 1C, 
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and Table S2 and Fig. S3 in the Supplementary 
Appendix).
Effect of DOCK2 Mutations on Protein 
Expression and T-Cell and B-Cell Signaling
Immunoblot analysis revealed no DOCK2 pro-
tein expression in T-cell lines obtained from 
Patient 1 and trace amounts in Patient 2; mark-
edly reduced levels of protein were detected in 
Epstein–Barr virus–transformed B cells obtained 
from Patient 3 (Fig. 1D, and Fig. S4A in the 
Supplementary Appendix). No biologic specimens 
from Patients 4 and 5 were available; however, 
overexpression of streptavidin–hemagglutinin–
tagged DOCK2 bearing the p.F744Cfs*27 muta-
tion (present in Patient 4) showed expression of 
a truncated DOCK2 protein (Fig. S4B in the 
Supplementary Appendix) that lacks the DOCK 
homology region 2 domain that is critical for the 
DOCK2 guanine nucleotide exchange factor 
function.
Previous studies involving mice have shown 
that Dock2 is essential for Rac1 activation down-
stream of the T-cell receptor.8,9 In our study, after 
activation of polyclonal human T-cell lines with 
an anti-CD3 monoclonal antibody, guanine tri-
phosphate–bound RAC1 was clearly detected in 
T cells from a healthy control and from Patient 2’s 
Figure 2. Defective RAC1 Activation, Lymphocyte Chemotaxis, and Actin Polymerization in Patients with DOCK2 
Deficiency.
Panel A shows impaired RAC1 activation in T-cell lines from Patients 1 and 2 and Patient 2’s mother (as compared 
with those from a healthy donor [control]), after stimulation of the T-cell receptor with the use of anti-CD3 mono-
clonal antibodies. One-way analysis of variance with Bonferroni correction was used to calculate the P values. T bars 
represent the standard-deviation values of three independent experiments. P<0.001 for all comparisons. Panel B 
shows reduced T-cell and B-cell migration in response to CCL21 or chemokine (C-X-C motif) ligand 12 (CXCL12) in 
Patients 1 and 2 as compared with a healthy control. NS denotes not stimulated. Panels C and D show reduced levels 
of polymerized, filamentous actin (F-actin) in Patients 1 and 2, as revealed by phalloidin staining in T cells (Panel C) 
and B cells (Panel D). MFI denotes mean fluorescence intensity.
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mother, but not from Patients 1 and 2 (Fig. 2A, 
and Fig. S5 in the Supplementary Appendix).
Chemokine-mediated cell migration is criti-
cally important during lymphocyte development, 
immune surveillance of lymph nodes, and recruit-
ment of immune cells to sites of inflammation. 
Previous experimental data suggested a role for 
DOCK2 in actin polymerization and chemotactic 
responses of T lymphocytes and B lymphocytes 
after chemokine stimulation.9,10 Indeed, the che-
motactic response of T cells and B cells obtained 
from Patients 1 and 2 was profoundly impaired 
(Fig. 2B). Furthermore, chemokine (C-X-C motif) 
ligand 12 (CXCL12)–induced actin polymeriza-
tion in T cells and B cells from Patients 1 and 2 
was impaired and delayed (Fig. 2C and 2D). 
Baseline levels of polymerized actin (filamentous 
actin [F-actin]) were also reduced in DOCK2-
deficient T lymphocytes and B lymphocytes from 
Patients 1 and 2 (Fig. 2C and 2D).
Defects in NK Cells and NK T Cells in Patients 
with DOCK2 Deficiency
Invasive viral infections were a prominent clini-
cal feature in Patients 2, 3, and 4. Patients with 
DOCK2 deficiency had normal numbers of CD3−
CD56+/CD16+ NK cells (Table 1), and NK cells 
from Patient 2 had a normal immunophenotype 
(Fig. S6 in the Supplementary Appendix). How-
ever, NK cells from Patients 1 and 2 showed 
impaired degranulation after stimulation with the 
human erythroleukemia cell line K562 (Fig. 3A).
The ability of NK cells to lyse virus-infected 
and tumor-target cells correlates with the func-
tionality of a variety of activating NK receptors 
interacting with distinct adaptor (DAP10 and 
DAP12) and signaling (CD3ζ, FcεRIγ) mole-
cules.11-13 The triggering of activating NK recep-
tors induces actin polymerization, activation of 
phosphatidylinositol-3-OH kinase, and phosphor-
ylation of extracellular signal-regulated kinase 
(ERK) and mitogen-activated protein–ERK (MEK), 
ultimately promoting NK-cell cytotoxicity.14
We analyzed NK-cell degranulation after en-
gagement of CD16, NKp30 (NK-cell p30-related 
protein), or NKp46 (NK-cell p46-related protein) 
— all of which use CD3ζ and FcεRIγ — or NKG2D 
(which recruits the DAP10 adaptor). We observed 
severely impaired degranulation in Patient 1 
(Fig. 3B) and moderately impaired degranulation 
in Patient 2, probably corresponding to residual 
amounts of DOCK2 protein in Patient 2’s hema-
topoietic cells (Fig. S4A in the Supplementary 
Appendix). Degranulation was also impaired in 
Patient 2’s interleukin-2–activated polyclonal NK 
cells after engagement of NKp44 (NK-cell p44-
related protein) (which uses DAP12) (Fig. S7 in 
the Supplementary Appendix). Furthermore, we 
observed reduced levels of F-actin in Patient 2’s 
NK cells after stimulation with anti-CD16 and 
anti-NKp46 monoclonal antibodies (Fig. 3C); 
these findings were reminiscent of observations 
in Dock2−/− mice.15 These reduced levels possibly 
reflected impaired tonal signaling through anti-
gen and chemokine receptors. Reduced phos-
phorylation of ERK1/2 and MEK and impaired 
actin polymerization were also detected in poly-
clonal NK cells from Patient 2 after cross-link-
ing of NKp30, NKp44 (Fig. 3D), CD16, and 
NKp46. NK cells are also involved in cytokine 
production.16 After overnight stimulation with 
interleukin-12 and interleukin-18, the proportion 
of NK cells expressing interferon-γ was markedly 
reduced in Patient 2 (Fig. 3E).
Finally, the number of circulating NK T cells 
was severely reduced in Patients 1 and 2 (Fig. S8 
in the Supplementary Appendix). Altogether, 
these data show that DOCK2 serves an essential 
role in NK and NK T-cell biology; these findings 
are consistent with similar observations in mice.17,18
Impaired Antiviral Interferon Responses  
in Patients with DOCK2 Deficiency
Human interferon-α/β and interferon-λ immu-
nity has been suggested to be essential in host 
defense against viral infections.19 Plasmacytoid 
dendritic cells are the major source of interferon-α 
in human blood in response to enveloped viruses 
and synthetic toll-like receptor 7 and toll-like 
receptor 9 agonists.20 Previous studies involving 
mice have shown that Dock2 serves an essential 
function in regulating interferon-α production 
in plasmacytoid dendritic cells without perturb-
ing development of these cells.15,21
Although a normal proportion of circulating 
plasmacytoid dendritic cells was detected in Pa-
tient 2 (Fig. S9 in the Supplementary Appendix), 
the production of interferon-α and interferon-λ in 
the peripheral-blood mononuclear cells (PBMCs) 
in Patients 1, 2, and 3 after stimulation with 
herpes simplex virus type 1 (HSV-1) or vesicular 
stomatitis virus (VSV) was markedly impaired 
(Fig. 4A, and Fig. S10 in the Supplementary Ap-
pendix). By contrast, similar amounts of inter-
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Figure 3. NK-Cell Cytotoxicity and Signaling Defects in Patients with DOCK2 Deficiency.
Panel A shows impaired NK-cell degranulation (as measured by CD107a surface expression) after stimulation with K562 cells in Patients 1 and 2, 
as compared with 10 healthy controls. Horizontal bars represent means, and T bars means ±SD. Panel B shows defective degranulation after 
triggering of activating NK-cell receptors in Patients 1 and 2, as compared with 6 healthy controls. Horizontal bars represent means, and T bars 
means ±SD. ND denotes not done. Panel C shows impaired actin polymerization after triggering of activating NK-cell receptors CD16 (top) and 
NKp46 (bottom). Panel D shows impaired extracellular signal-regulated kinase (ERK) and mitogen-activated protein–ERK (MEK) phosphor-
ylation in NK cells from Patient 2 after triggering of activating receptors, as detected by means of flow cytometry. Panel E shows decreased 
interferon-γ production after NK-cell stimulation with interleukin-12 and interleukin-18 in Patient 2, as compared with a healthy control.
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leukin-6 were produced by PBMCs in samples 
obtained from patients with DOCK2 deficiency 
and from healthy donors (Fig. 4A, and Fig. S10 
in the Supplementary Appendix). Altogether, 
these data indicate that in addition to T cells, 
NK cells, and NK T cells, plasmacytoid den-
dritic cells may also be defective in patients with 
DOCK2 deficiency; this may also contribute to 
the patients’ viral susceptibility.
Although DOCK2 is preferentially expressed 
in hematopoietic cells,22 low levels of expression 
were detected in fibroblasts from healthy con-
trols, but not from Patients 1 and 2 (Fig. S4A in 
the Supplementary Appendix). Only minimal 
expression was detected in fibroblasts from Pa-
tient 3 (Fig. S4A in the Supplementary Appen-
dix). To investigate whether DOCK2 contributes 
to cell-intrinsic antiviral responses in nonhema-
topoietic tissues, we studied simian virus 40 
(SV40)–immortalized fibroblasts from Patients 1, 
2, and 3 and from healthy controls. After infec-
tion with VSV or encephalomyocarditis virus, we 
found enhanced levels of viral replication and 
decreased viability of DOCK2-deficient SV40 fi-
broblasts (Fig. 4B, and Fig. S11 in the Supple-
mentary Appendix); similar results were ob-
served in SV40 fibroblasts from patients with 
toll-like receptor 3 or signal transducer and ac-
tivator of transcription 1 deficiency (Fig. 4B, and 
Fig. S11 in the Supplementary Appendix), which 
affect the production of or the response to 
interferon-α/β and interferon-λ, respectively.23
Both treatment with recombinant interferon 
alfa-2b (Fig. 4B) and lentiviral-mediated wild-type 
DOCK2 expression (Fig. 4C) protected DOCK2-
deficient fibroblasts from virus-induced cell death 
(Fig. 4D). The DOCK2 mutations may therefore 
also impair cell-intrinsic, nonhematopoietic im-
munity, at least in fibroblasts and in response to 
some viruses.
Discussion
In this study, we showed that biallelic mutations 
in DOCK2 were the molecular cause of a distinc-
tive type of combined immunodeficiency that is 
characterized by early-onset, invasive bacterial 
and viral infections; T-cell lymphopenia; impaired 
T-cell, B-cell, and NK-cell function; and defective 
interferon immunity in both hematopoietic and 
nonhematopoietic cells. Our results also indicate 
that this disease can be detected at birth with 
newborn screening for severe combined immuno-
deficiency (Table 1) and can be cured by means of 
HSCT (Fig. S12 in the Supplementary Appendix).
The observation that DOCK2 deficiency in 
humans leads to impaired RAC1 activation and 
to defects in actin polymerization, T-cell prolif-
eration, chemokine-induced lymphocyte migra-
tion, and NK-cell degranulation confirms and ex-
tends similar observations in Dock2−/− mice.9,10,17,24 
It also highlights the essential role of regulated 
actin dynamics for immune-cell function, a role 
that is also evident with respect to other com-
bined immunodeficiencies involving defective ac-
tin polymerization such as the Wiskott–Aldrich 
syndrome,25 as well as with respect to deficiency 
of Wiskott–Aldrich syndrome protein–interacting 
protein (WIP),26 DOCK8 protein,27 the protein 
encoded by the Ras homologue family member H 
(RHOH),28 and macrophage-stimulating 1 growth 
factor (MST1) protein.29,30
The occurrence of invasive viral infections, 
including disseminated vaccine-strain varicella, 
Figure 4 (facing page). Impaired Interferon Responses to 
Viruses in DOCK2-Deficient Leukocytes and Fibroblasts.
Panel A shows impaired interferon-α and interferon-λ 
production by DOCK2-deficient peripheral-blood mono-
nuclear cells (PBMCs) after exposure to either herpes 
simplex virus 1 (HSV-1) or vesicular stomatitis virus 
(VSV) for 24 hours each. By contrast, production of in-
terleukin-6 by the patients’ PBMCs was similar to that 
in the PBMCs of the healthy donors (controls) and 
served as an assay control. NI denotes not infected. 
Panel B shows increased encephalomyocarditis virus 
(EMCV)–induced cell death of DOCK2-deficient simian 
virus 40 (SV40) fibroblasts (left) and rescue by the ad-
dition of interferon alfa-2b (right). Toll-like receptor 3 
(TLR3)–deficient and signal transducer and activator 
of transcription 1 (STAT1)–deficient SV40 fibroblast 
cell lines served as examples of defective interferon-
dependent antiviral immunity. I bars represent the 
standard-deviation values of triplicate measurements 
from one representative experiment of three experi-
ments performed. MOI denotes multiplicity of infec-
tion. Panel C shows immunoblot analysis of protein 
 lysates obtained from SV40 fibroblasts from a healthy 
donor (control) and Patient 2, as well as from mock-
transduced (Mock) and DOCK2-transduced fibroblasts 
from Patient 2. Panel D shows rescue of EMCV-induced 
cell death of SV40 fibroblasts from Patient 2 by exoge-
nous expression of wild-type DOCK2. STAT1-deficient 
fibroblasts were used as a negative control. The data 
in Panels B and D show one representative experiment 
of three independent experiments with technical tripli-
cates carried out in each experiment.
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was a prominent feature in patients with DOCK2 
deficiency. Human antiviral immunity is criti-
cally dependent on intact T-cell function as well 
as on innate immune responses, as observed in 
patients with genetic defects affecting T-cell, 
NK-cell, NK T-cell, and dendritic-cell develop-
ment, function, or both,1,31 or with mutations 
affecting production of (or response to) inter-
feron-α, interferon-β, and interferon-λ in both 
hematopoietic and nonhematopoietic cells.32 We 
observed defective interferon-α/β and inter-
feron-λ responses in both hematopoietic and 
nonhematopoietic cells in patients with DOCK2 
deficiency. Plasmacytoid dendritic cells are the 
most potent interferon-α–producing cells.33 Se-
vere reduction of splenic and lymph-node plas-
macytoid dendritic cells and of their capability 
for interferon-α production were observed in 
Dock2−/− mice.15,21 Here we show impaired inter-
feron-α and interferon-λ production in DOCK2-
deficient PBMCs after stimulation with HSV-1 or 
VSV, possibly reflecting a defect of plasmacytoid 
dendritic cells. Therefore, we speculate that 
treatment with interferon alfa-2b might be bene-
ficial in patients with DOCK2 deficiency who 
have severe viral infections.
Furthermore, our study suggests a role for 
DOCK2 in antiviral responses in nonhematopoi-
etic cells. DOCK2 deficiency in nonhematopoietic 
cells may contribute to the pathogenesis of se-
vere viral infections. Normalization of immuno-
logic abnormalities and resolution of infections 
were observed in Patients 1, 2, and 5 after HSCT 
(Fig. S12 in the Supplementary Appendix). This 
finding implies that correction of hematopoietic 
cells may be sufficient to rescue the clinical phe-
notype, possibly by providing a source of cells 
producing interferon-α/β (e.g., plasmacytoid den-
dritic cells) and therefore complementing the 
defect in nonhematopoietic tissues.
K. pneumoniae sepsis was the cause of death in 
Patient 4. Susceptibility to invasive bacterial in-
fections in patients with DOCK2 deficiency may 
reflect impaired function of neutrophil granulo-
cytes in addition to impaired antibody produc-
tion. Defective neutrophil chemotaxis has been 
reported in Dock2−/− mice.34 Because of a lack of 
primary material, we could not test whether a 
similar defect existed in the patients in our study.
Mutations in DOCK8, another member of the 
DOCK family of proteins, have been identified in 
patients with another form of combined immu-
nodeficiency.35,36 Similarities and important dif-
ferences have been observed between patients 
with DOCK2 deficiency and those with DOCK8 
deficiency. Both conditions are characterized by 
recurrent bacterial and viral infections36 and are 
associated with T-cell lymphopenia,36 defective 
NK-cell function,37 aberrant NK T-cell survival 
and function,38 and impaired antibody respons-
es.39 However, the natural course of DOCK2 de-
ficiency appears to be more severe than that of 
DOCK8 deficiency. Although DOCK8 deficiency 
is characterized mostly by cutaneous viral infec-
tions,36 patients with DOCK2 deficiency have 
early-onset, life-threatening, invasive viral and 
bacterial infections. Furthermore, severe food 
allergies, eczema, and autoimmunity are com-
monly observed in patients with DOCK8 defi-
ciency,36,40,41 whereas none of the patients with 
DOCK2 deficiency had such manifestations.
In summary, we have identified DOCK2 defi-
ciency as a pleiotropic immunodeficiency lead-
ing to early-onset, invasive bacterial and viral 
infections. The broad spectrum of infections 
observed in patients with DOCK2 deficiency 
highlights the effect of DOCK2 function on sev-
eral aspects of immunity and arouses possible 
concern about the application of new immuno-
suppressive agents targeting DOCK2.42 Our ob-
servations indicate that HSCT can provide a cure 
for this immunodeficiency.
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